AKBLF saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on January 08, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 18 instances where the indicator turned negative. In of the 18 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The Momentum Indicator moved below the 0 level on January 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on AKBLF as a result. In of 21 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Aroon Indicator for AKBLF entered a downward trend on December 20, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AKBLF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.398) is normal, around the industry mean (14.744). P/E Ratio (42.007) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.853). AKBLF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (6.169) is also within normal values, averaging (264.079).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Industry Biotechnology
A.I.dvisor tells us that AKBLF and MNPR have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AKBLF and MNPR's prices will move in lockstep.
Ticker / NAME | Correlation To AKBLF | 1D Price Change % | ||
---|---|---|---|---|
AKBLF | 100% | N/A | ||
MNPR - AKBLF | 29% Poorly correlated | -6.36% | ||
MSCLF - AKBLF | 27% Poorly correlated | +1.17% | ||
IOVA - AKBLF | 26% Poorly correlated | +2.60% | ||
SMMT - AKBLF | 25% Poorly correlated | +4.62% | ||
VBIZF - AKBLF | 24% Poorly correlated | N/A | ||
More |